GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
G

Gossamer Bio GOSS · USD

Health Care · US listing · 🇺🇸 United States

Compare

10.72

-4.54%

Close of 20 Nov 2026, in USD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

Price performance

Chart by TradingView, with its own licensed prices

Gossamer Bio — daily GOSS Delayed
Market value
$30.6m
Last close × shares
Volume
191.4k
Shares, 20 Nov 2026

About Gossamer Bio

From its filings with the US Securities and Exchange Commission

SEC filings

Gossamer Bio is based in San Diego, California and is incorporated in Delaware. Its shares trade on Nasdaq under the ticker GOSS. The SEC classifies its business as pharmaceutical preparations. In the fiscal year to 31 December 2025, it reported revenue of $48.5m and a net loss of $170.4m. At that date it held total assets of $172.2m and shareholders' equity of −$122.8m.

In its own words

Our founders and management team have held senior positions at leading biopharmaceutical companies and possess substantial experience and expertise across the spectrum of drug development and commercialization.

Faheem Hasnain is our Co-Founder and has served as our Chief Executive Officer since November 2020 and as our Chairman since our inception. Mr. Hasnain also served as our Chief Executive Officer from our inception through July 2018 and our Executive Chairman from July 2018 through June 2019. Prior to co-founding Gossamer Bio, Mr. Hasnain served as President, CEO and as a Director of Receptos, Inc. from November 2010 to August 2015. Receptos was a public company formed in 2009 focused on developing treatments in immunology and metabolic disorders and was purchased by Celgene Corporation in August 2015. Previously, Mr. Hasnain was the President and Chief Executive Officer and a director of Facet Biotech Corporation, a biology-driven antibody company with a focus in multiple sclerosis and oncology. He held that position from December 2008 until the company's acquisition by Abbott Laboratories in April 2010.

Quoted from its 10-K, filed 17 Mar 2026. Read the filing on SEC.gov ↗

More about Gossamer Bio →

Latest on Gossamer Bio

Our reporting

Next results

16 Mar 2027

Due on 16 Mar 2027. Analysts expect earnings of -2.65 a share.

Other Health Care listings

Scenario calculator

Try your own numbers. This is arithmetic, not a forecast.

Interactive

Gain or loss

—

Return

—

Leaves out fees, taxes and financing.

Frequently asked questions

What is Gossamer Bio's ticker?

Gossamer Bio trades as GOSS on its US listing, under ISIN US38341P1021.

What was Gossamer Bio's last closing price?

10.72 on 20 Nov 2026. The figure is in USD and is never converted.

Sources and methodology

Chart
TradingView
Close and company data
SEC filings and our data supplier
News
Our reporting

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.